Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 115

Sort by

Sort Order Select

Journal Articles

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Ying Sheng, Chiung-Yu Huang, PhD, Sophia Byslma, BS, Kelsey Natsuhara, MD, Dhruba Biswas, Mimi Lo, PharmD, BCPS, BCOP, Weiyun Z. Ai, Lawrence D Kaplan, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Charalambos Andreadis, MD MSCE, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-138940

Published: 2020

Journal Articles

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Jeffrey Marsal, BS, Rahul Banerjee, MD, Chiung-Yu Huang, PhD, Mimi Lo, PharmD, BCPS, BCOP, Vanessa E Kennedy, MD, Shagun Arora, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Sandy W. Wong, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138618

Published: 2020

Journal Articles

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Swetha Kambhampati, MD, Sandy W. Wong, MD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Priya Choudhry, PhD, William Karlon, MD PhD, Arun P. Wiita, MD PhD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-138869

Published: 2020

Journal Articles

Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma

Vanessa E Kennedy, MD, Christopher Wong, Chiung-Yu Huang, PhD, Jeffrey L. Wolf, MD, Thomas Martin, MD, Nina Shah, MD, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-142612

Published: 2020

Journal Articles

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Nirav N. Shah, MD, Ahmad H. Mattour, MD, Leslie L. Popplewell, MD FACP, Charalambos Andreadis, MD, Jason M. Melear, MD, Alexander I. Spira, PhD MD FACP, Jonah Shulman, MD, Sudhir Manda, MD, John M. Burke, MD, Saurabh Chhabra, MD, Jeff P Sharman, MD, Amrita Krishnan, MD, Nina Shah, MD, Clifford DiLea, RPh, Pharm.D., Jason Kuriakose, MBA, Craig Jerome Berman, MD, Shannon L. Matheny, PhD, John P. Leonard, MD, Arturo Molina, MDMS

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-139829

Published: 2020

Journal Articles

Incidence, Management and Outcomes of Arterial and Venous Thromboembolism after Chimeric Antigen Receptor Modified T Cells for B-Cell Lymphoma and Multiple Myeloma

Anna L. Parks, MD, Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Charalambos Andreadis, MD, Lissa Gray, MSN, Sandy W. Wong, MD, Nina Shah, MD, Margaret C. Fang, MD MPH

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-136782

Published: 2020

Journal Articles

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Joaquin Martinez Lopez, Rafael Alonso Fernández, Sandy W. Wong, MD, Rafael Rios, MD PhD, Nina Shah, MD, Maria Teresa Cedena Romero, MD PhD, Yanira Ruiz-Heredia, Jose M. Sanchez, MD, Santiago Barrio Garcia, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-140352

Published: 2020

Journal Articles

Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

Ankit Kansagra, MD, Yi Lin, MD PhD, Jesus G. Berdeja, MD, Nina Shah, MD, Albert Oriol, MD, Ibrahim Yakoub-Agha, Hermann Einsele, MD, Alessandro Rambaldi, MD, Anna Truppel-Hartmann, MD, Everton Rowe, PhD, Julie Wang, PharmD, PhD, Amit Agarwal, MD PhD, Timothy B. Campbell, MD PhD, Sagar Lonial, MD FACP

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134383

Published: 2020

Journal Articles

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142426

Published: 2020

Journal Articles

Phase 2 Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Stage I Results

Caitlin L. Costello, MD, Benjamin Brookhart, Matthew J. Wieduwilt, MD PhD, Nina Shah, MD, Carolyn Mulroney, MD, Edward D. Ball, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-143147

Published: 2020

Journal Articles

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Saad Z. Usmani, MDMBBS,MBA, Jesus G. Berdeja, MD, Anna Truppel-Hartmann, MD, Marie-Laure Casadebaig, Honeylet Wortman-Vayn, Suresh G. Shelat, PhD, Steven Novick, MDPhD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-139009

Published: 2020

Journal Articles

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

Rahul Banerjee, MD, Ann Lazar, PhD MS, Lisa Dunn, RN, Jennifer Knoche, RN, Kelly Jean Brassil, PhD MA, MSN, RN, Dhiren Patel, PharmD, Lindsey Jackson, MPH, CPH, Mimi Lo, PharmD, BCPS, BCOP, Anand Dhruva, MD, Shagun Arora, MD, Sandy W. Wong, MD, Jeffrey L. Wolf, MD, Thomas Martin, III, MD, Nina Shah, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-134163

Published: 2020

Journal Articles

A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma

Nina Shah, MD, Dieter Ayers, Faith E. Davies, Shannon Cope, Ali Mojebi, Kejal Parikh, Devender Dhanda, Parameswaran Hari, MD MRCP, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-136730

Published: 2020

Journal Articles

Adoptive Therapy with Cord Blood T Regulatory Cells Enhances Anti-Myeloma Efficacy of T Cell Based Immunotherapies

Mitsutaka Nishimoto, MD PhD, Li Li, MD, Meixian Huang, MD,PhD, Mi-Ae Lyu, PhD, Ke Zeng, MD, Hongbing Ma, MD PhD, Tara Sadeghi, Sairah Ahmed, MD, Nina Shah, MD, Krina K. Patel, MD, Simrit Parmar, MD, MSCI

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-143142

Published: 2020

Journal Articles

Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study

Alex Ge, Chiung-Yu Huang, PhD, Thomas Martin, III, MD, Jeffrey L. Wolf, MD, Nina Shah, MD, Sandy W. Wong, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-141525

Published: 2020

Journal Articles

Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation

Surbhi Sidana, MD, Shaji K. Kumar, MD, Raphael Fraser, PhD, Noel Estrada-Merly, MS, Maxim Norkin, MD PhD, Sergio Giralt, MD, Muzaffar H. Qazilbash, MD, Nina Shah, MD, Anita D'Souza, MD MS

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-139017

Published: 2020

Journal Articles

Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial

Michel Delforge, Nina Shah, MD, Paula Rodriguez-Otero, Parameswaran Hari, MD MRCP, Julia Braverman, PhD, Andrew Trigg, Payal Patel, Liping Huang, PhD, Kristen Hege, Sujith Dhanasiri

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-136677

Published: 2020

Journal Articles

A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-142680

Published: 2020

Journal Articles

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-140410

Published: 2020

Journal Articles

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Caitlin L. Costello, MD, Adam D. Cohen, MD, Krina K. Patel, MD, Syed S Ali, MD, Jesus G. Berdeja, MD, Nina Shah, MD, Siddhartha Ganguly, MD, Mehmet Hakan Kocoglu, MD, Mehrdad Abedi, MD, Eric M. Ostertag, MD PhD, Chris E Martin, PhD, Majid Ghoddussi, PhD, Devon J Shedlock, PhD, Joanne McCaigue, M.S., Hamid Namini, PhD, Sreeni Yalamanchili, Matthew A. Spear, MD, Tara K. Gregory, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142695

Published: 2020

NARROW

Infectious Complications of BCMA-Targeted and CD19-Targeted Chimeric Antigen Receptor T-Cell Immunotherapy

Patterns of Tocilizumab Use Among Myeloma Patients Receiving Bcma-Directed Therapies: Effect on Day 30 Outcomes

Phase II Study of Daratumumab in Combination with Azacitidine and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Daratumumab: Darazadex

Macrophage Activation Syndrome-like Manifestations (MAS-L) Following BCMA-Directed CAR T-Cells in Multiple Myeloma

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Incidence, Management and Outcomes of Arterial and Venous Thromboembolism after Chimeric Antigen Receptor Modified T Cells for B-Cell Lymphoma and Multiple Myeloma

Making Clinical Decisions to Change Therapy Using Measurable Residual Disease Improves the Outcome in Multiple Myeloma

Characterization of Cytokine Release Syndrome in the KarMMa Study of Idecabtagene Vicleucel (ide-cel, bb2121) for Relapsed and Refractory Multiple Myeloma

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Phase 2 Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Stage I Results

KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma

Digital Life Coaching for Myeloma Patients Undergoing Transplantation

A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma

Adoptive Therapy with Cord Blood T Regulatory Cells Enhances Anti-Myeloma Efficacy of T Cell Based Immunotherapies

Outcomes of Plasma Cell Leukemia Patients in the Era of Next-Generation Novel Agents: A Single-Center Retrospective Cohort Study

Maintenance Use Is More Important Than the Choice of Bortezomib-Based Triplet Induction in Newly Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplantation

Health State Utility Valuation in Patients with Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma Treated with the Bcma-Directed CAR T Cell Therapy, Idecabtagene Vicleucel (ide-cel, bb2121): Results from the Karmma Trial

A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS

Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes

Phase 1/2 Study of the Safety and Response of P-BCMA-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME) with Novel Therapeutic Strategies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only